These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 4257264)

  • 21. The proteolysis of fibrinogen by plasmin: the identification of thrombin-clottable fibrinogen derivatives which polymerize abnormally.
    Fletcher AP; Alkjaersig N; Fisher S; Sherry S
    J Lab Clin Med; 1966 Nov; 68(5):780-802. PubMed ID: 4224270
    [No Abstract]   [Full Text] [Related]  

  • 22. Large scale preparation of S-carboxymethylated chains of human fibrin and fibrinogen and the occurrence of -chain variants.
    Henschen A; Edman P
    Biochim Biophys Acta; 1972 Apr; 263(2):351-67. PubMed ID: 5031163
    [No Abstract]   [Full Text] [Related]  

  • 23. [Immunological and hemocoagulative characteristics of serums of rabbits immunized with prothrombin, fibrinolysin (plasmin), fibrinogen and thrombin. (Experimental immuno-coagulopathy)].
    DE NICOLA P; ZANGAGLIA O; SOARDI F
    Riv Emoter Immunoematol; 1959; 6():161-78. PubMed ID: 13814944
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of various proteolytic enzymes on fibrinogen.
    Latallo ZS; Teisseyre E; Wegrzynowicz Z; Kopec M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1971; 95(2):158-66. PubMed ID: 4106004
    [No Abstract]   [Full Text] [Related]  

  • 25. Fate of fibrinopeptides in the reaction between human plasmin and fibrinogen.
    Lahiri B; Shainoff JR
    Biochim Biophys Acta; 1973 Mar; 303(1):161-70. PubMed ID: 4267201
    [No Abstract]   [Full Text] [Related]  

  • 26. Characterisation of large fragments rich in disulphide bridges from CNBr-treated products of exhaustive proteolysis of fibrinogen by plasmin.
    Dudek-Wojciechowska GA; Kloczewiak M; Latallo ZS; Kopeć M
    Biochim Biophys Acta; 1973 Feb; 295(2):536-42. PubMed ID: 4266974
    [No Abstract]   [Full Text] [Related]  

  • 27. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.
    Dombret H; Scrobohaci ML; Daniel MT; Micléa JM; Castaigne S; Chomienne C; Fenaux P; Degos L
    Leukemia; 1995 Jan; 9(1):19-24. PubMed ID: 7531260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.
    Pizzo SV; Schwartz ML; Hill RL; McKee PA
    J Clin Invest; 1972 Nov; 51(11):2841-50. PubMed ID: 4263497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A molecular model for the proteolysis of human fibrinogen by plasmin.
    Mills DA
    Biochim Biophys Acta; 1972 May; 263(3):619-30. PubMed ID: 4260761
    [No Abstract]   [Full Text] [Related]  

  • 31. Generation of forms of fragment E with differing thrombin-binding properties during digestion of fibrinogen by plasmin.
    Goodwin CA; Kakkar VV; Scully MF
    Biochem J; 1992 Feb; 281 ( Pt 3)(Pt 3):613-8. PubMed ID: 1531588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nature of the high molecular weight fraction of fibrinolytic digests of human fibrinogen.
    Jamieson GA; Gaffney PJ
    Biochim Biophys Acta; 1968 Jan; 154(1):96-109. PubMed ID: 4230213
    [No Abstract]   [Full Text] [Related]  

  • 33. Biochemical and biophysical aspects of human platelet adhesion to collagen fibers.
    Lyman B; Rosenberg L; Karpatkin S
    J Clin Invest; 1971 Sep; 50(9):1854-63. PubMed ID: 5564392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of soluble and immobilized plasmin on fibrinogen and platelets.
    Senatore F; Shankar H; Ho CH; Avantsa S; Allon M; Posteraro R
    Thromb Haemost; 1990 Nov; 64(3):445-9. PubMed ID: 2151408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physicochemical and biological properties of human and canine plasmins.
    Takeda Y; Nakabayashi M
    J Clin Invest; 1974 Jan; 53(1):154-62. PubMed ID: 4128408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Structure of fibrinogen in view of the properties and structure of proteolytic products of degradation by plasmin].
    Budzyński AZ
    Postepy Hig Med Dosw; 1969; 23(3):293-369. PubMed ID: 4240986
    [No Abstract]   [Full Text] [Related]  

  • 37. VARIABILITY OF THE ANTICOAGULANT FRACTION OF INCUBATED FIBRINOGEN.
    TRIANTAPHYLLOPOULOS E; TRIANTAPHYLLOPOULOS DC
    Am J Physiol; 1965 Mar; 208():521-7. PubMed ID: 14264744
    [No Abstract]   [Full Text] [Related]  

  • 38. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
    Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
    Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Degradation of fibrinogen by plasmin: physicochemical characteristics and their correlation to antithrombic activity.
    Triantaphyllopoulos E
    Thromb Diath Haemorrh Suppl; 1973; 56():91-112. PubMed ID: 4281941
    [No Abstract]   [Full Text] [Related]  

  • 40. A STANDARD CLOT METHOD FOR THE ASSAY OF PLASMINOGEN ACTIVATORS, ANTI-ACTIVATORS, AND PLASMIN.
    HAWKEY CM; STAFFORD JL
    J Clin Pathol; 1964 Mar; 17(2):175-81. PubMed ID: 14149945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.